

# Dafna D Gladman

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6737587/dafna-d-gladman-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

547  
papers

43,454  
citations

92  
h-index

196  
g-index

702  
ext. papers

51,060  
ext. citations

5.5  
avg, IF

7.38  
L-index

#	Paper	IF	Citations
547	Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. <i>Arthritis and Rheumatism</i> , <b>1992</b> , 35, 630-40		3596
546	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2677-86		2688
545	Classification criteria for psoriatic arthritis: development of new criteria from a large international study. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2665-73		2136
544	The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 39, 363-9		1688
543	Systemic lupus erythematosus disease activity index 2000. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 288-91	4.1	1602
542	Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. <i>Nature Genetics</i> , <b>2009</b> , 41, 199-204	36.3	1038
541	Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 3279-89		712
540	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , <b>2012</b> , 44, 1341-8	36.3	681
539	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. <i>Nature Genetics</i> , <b>2011</b> , 43, 761-7	36.3	646
538	Psoriatic Arthritis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 957-970	59.2	586
537	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. <i>Nature Genetics</i> , <b>2013</b> , 45, 730-8	36.3	551
536	Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 1227-36		517
535	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 809-13		505
534	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1400-1412	9.5	488
533	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1060-71	9.5	485
532	Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 976-86		467
531	Epidemiology of psoriatic arthritis in the population of the United States. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 53, 573	4.5	414

530	Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 556-62		354
529	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1151-1159	2.4	344
528	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 79-87	2.4	341
527	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 1031-42	4.5	329
526	Psoriasis. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16082	51.1	327
525	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 3-17	2.4	320
524	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1020-6	2.4	305
523	Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 1939-50		298
522	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, 729-735	4.5	287
521	Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. <i>Journal of Immunology</i> , <b>2002</b> , 169, 2818-22	5.3	287
520	Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. <i>Nature Genetics</i> , <b>2010</b> , 42, 991-5	36.3	283
519	Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1525-1536	59.2	276
518	Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 1868-72		269
517	Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2001</b> , 45, 151-8		257
516	Genome-wide association analysis identifies three psoriasis susceptibility loci. <i>Nature Genetics</i> , <b>2010</b> , 42, 1000-4	36.3	251
515	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1706-13	2.4	250
514	Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. <i>Arthritis and Rheumatism</i> , <b>1998</b> , 41, 1103-10		246
513	Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 476-88		231

512	Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 2152-8	4.1	229
511	Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. <i>Journal of Immunology</i> , <b>2004</b> , 173, 4273-6	5.3	224
510	Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 939-48		218
509	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 252-62	3.9	210
508	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 863-8		203
507	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , <b>2013</b> , 42, 130-5	15.5	194
506	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 986-91	2.4	192
505	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 251-265.e195	4.5	186
504	Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. <i>American Journal of Human Genetics</i> , <b>2015</b> , 97, 816-36	11	185
503	Accrual of organ damage over time in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1955-9	4.1	185
502	Lupus and pregnancy studies. <i>Arthritis and Rheumatism</i> , <b>1993</b> , 36, 1392-7		183
501	Malignancy in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 39, 1050-4		179
500	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 5-32	9.5	178
499	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , <b>2017</b> , 8, 16021	17.4	171
498	Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1729-35	4.7	169
497	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , <b>2015</b> , 6, 7146	17.4	164
496	Lupus retinopathy. Patterns, associations, and prognosis. <i>Arthritis and Rheumatism</i> , <b>1988</b> , 31, 1105-10		161
495	Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. <i>American Journal of Human Genetics</i> , <b>2014</b> , 95, 162-72	11	151

494	Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2504-17		151
493	Assessment of patients with psoriatic arthritis: a review of currently available measures. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 24-35		151
492	Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 2152-4	2.4	145
491	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1167-70	4.1	144
490	Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. <i>Rheumatology</i> , <b>2012</b> , 51, 571-6	3.9	143
489	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 673-680	2.4	138
488	Depression and anxiety in psoriatic disease: prevalence and associated factors. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 887-96	4.1	138
487	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 2-29	4.7	137
486	Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. <i>Nature Communications</i> , <b>2017</b> , 8, 15382	17.4	136
485	CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. <i>American Journal of Human Genetics</i> , <b>2003</b> , 73, 677-81	11	136
484	Association of interleukin-23 receptor variants with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1020-5		134
483	Vitamin D insufficiency in a large female SLE cohort. <i>Lupus</i> , <b>2010</b> , 19, 13-9	2.6	131
482	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1550-1558	2.4	129
481	Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. <i>Nature Communications</i> , <b>2015</b> , 6, 7001	17.4	122
480	Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 1638-45		122
479	The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 915-23	9.5	119
478	Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. <i>Rheumatology</i> , <b>2010</b> , 49, 1399-405	3.9	118
477	Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. <i>American Journal of Medicine</i> , <b>1979</b> , 66, 210-5	2.4	117

476	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1502-9	2.4	115
475	Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. <i>Nature Genetics</i> , <b>2015</b> , 47, 1085-90	36.3	112
474	Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 936-9	2.4	112
473	Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 813-7	2.4	108
472	Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1977-82	4.1	108
471	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , <b>2018</b> , 392, 2367-2377	4.0	107
470	Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 50-5	2.4	104
469	Quality of life over time in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 181-5		104
468	Association between the interleukin-1 family gene cluster and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2321-5		104
467	Predictors for radiological damage in psoriatic arthritis: results from a single centre. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 370-6	2.4	104
466	Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 479-88	4.1	101
465	Psoriatic arthritis. <i>Dermatologic Therapy</i> , <b>2009</b> , 22, 40-55	2.2	101
464	Premature atherosclerosis in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , <b>2000</b> , 26, 257-78	2.4	101
463	Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1689-94	2.4	100
462	Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. <i>Rheumatology</i> , <b>2012</b> , 51, 552-6	3.9	100
461	Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 62, 291-9	4.5	98
460	Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 1560-3		98
459	Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 824-7	4.1	97

458	Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 970-6	4.7	94
457	Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1112-1124	9.5	94
456	Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. <i>Rheumatology</i> , <b>2011</b> , 50, 25-31	3.9	93
455	The effect of pregnancy on lupus nephritis. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 3941-6		92
454	The effect of lupus nephritis on pregnancy outcome and fetal and maternal complications. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 754-8	4.1	91
453	Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1822-7	4.1	90
452	Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1152-8		90
451	Psoriatic arthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>1998</b> , 24, 829-44, x	2.4	90
450	Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 1133-40	4.3	89
449	Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. <i>Arthritis and Rheumatism</i> , <b>1994</b> , 37, 1212-20		89
448	The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. <i>Arthritis and Rheumatism</i> , <b>1995</b> , 38, 845-50		88
447	Natural history of psoriatic arthritis. <i>Baillieres Clinical Rheumatology</i> , <b>1994</b> , 8, 379-94		87
446	Improved survival in psoriatic arthritis with calendar time. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 2708-14		85
445	Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 69-78	4.1	84
444	Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 363-371	8.1	83
443	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 138-42	2.4	83
442	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1235-42		83
441	Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 70-5	4.1	83

440	Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 898-903	4.1	82
439	Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1091-7	4.7	81
438	Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1685-1691	4.7	80
437	Clinical Features and Diagnostic Considerations in Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2015</b> , 41, 569-79	2.4	80
436	The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 831-41	4.1	79
435	Immunogenetic profile of patients with psoriatic arthritis varies according to the age at onset of psoriasis. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 822-3		79
434	Axial disease in psoriatic arthritis. <i>Current Rheumatology Reports</i> , <b>2007</b> , 9, 455-60	4.9	78
433	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1837-47	9.5	77
432	A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time?. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 840-9		76
431	Prolonged remission in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 1467-72	4.1	76
430	Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1956-61	2.4	75
429	Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 367-377	4.1	74
428	HLA-C locus alleles in patients with psoriatic arthritis (PsA). <i>Human Immunology</i> , <b>1999</b> , 60, 259-61	2.3	73
427	The rate and pattern of organ damage in late onset systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 913-7	4.1	71
426	Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1777-85	2.4	70
425	A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). <i>Lupus</i> , <b>1996</b> , 5, 190-5	2.6	70
424	Genetics of psoriasis and psoriatic arthritis: update and future direction. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 1449-53	4.1	70
423	Axial psoriatic arthritis: update on a longterm prospective study. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2744-50	4.1	69



422	Prolonged clinical remission in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1808-16	4.1	68
421	The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1990-6	2.4	67
420	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1740-5	4.1	67
419	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1522-1528	4.1	66
418	Excessive paternal transmission in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 1228-31		66
417	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2887-97		65
416	SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. <i>Lupus</i> , <b>2011</b> , 20, 67-70	2.6	65
415	Prevalence of malignancy in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 82-7		64
414	Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 974-85		64
413	ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1627-9	2.4	63
412	The Development of Psoriatic Arthritis in Patients With Psoriasis Is Preceded by a Period of Nonspecific Musculoskeletal Symptoms: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 622-629	9.5	63
411	Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1680-6	2.4	62
410	Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1349-56	4.1	62
409	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, R156	5.7	61
408	Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 809-15	4.1	61
407	Psoriatic arthritis. <i>Expert Opinion on Investigational Drugs</i> , <b>2000</b> , 9, 1511-22	5.9	61
406	Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. <i>Nature Communications</i> , <b>2018</b> , 9, 4178	17.4	61
405	Psoriatic Arthritis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2095-6	59.2	60

404	Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e000239	4.6	60
403	Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 511-8	4.7	60
402	Is the MADrid Sonographic Enthesitis Index useful for differentiating psoriatic arthritis from psoriasis alone and healthy controls?. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 466-72	4.1	59
401	Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. <i>Arthritis Research and Therapy</i> , <b>2010</b> , 12, R113	5.7	59
400	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 267-74	4.7	57
399	Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 688-97	4.1	57
398	Qualifying unmet needs and improving standards of care in psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1759-66	4.7	57
397	The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 715-20	2.4	57
396	Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1357-9	4.1	57
395	Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 2160-4	2.4	57
394	Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2454-61	4.1	57
393	Psoriatic arthritis. <i>Dermatologic Therapy</i> , <b>2004</b> , 17, 350-63	2.2	57
392	The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 1126-31	4.1	57
391	Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 45, 604-10	5.3	56
390	Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 578-82	2.4	56
389	Incidence of arthritis in a prospective cohort of psoriasis patients. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 619-22	4.7	56
388	Association of interleukin 23 receptor variants with psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 137-40	4.1	56
387	Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1898-905	4.1	56

386	Diagnosis and management of psoriatic arthritis. <i>Drugs</i> , <b>2002</b> , 62, 2447-57	12.1	56
385	HLA-DR4 in giant cell arteritis: association with polymyalgia rheumatica syndrome. <i>Arthritis and Rheumatism</i> , <b>1987</b> , 30, 1293-7		56
384	Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 469-71	4.1	56
383	SLEDAI-2K for a 30-day window. <i>Lupus</i> , <b>2010</b> , 19, 49-51	2.6	55
382	Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 264-72	4.7	54
381	Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 275-84	4.1	54
380	Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000031	4.6	53
379	Clinical aspects of the spondyloarthropathies. <i>American Journal of the Medical Sciences</i> , <b>1998</b> , 316, 234-82.2		53
378	All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 802-806	2.4	52
377	Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 1504-9		52
376	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1530-6	2.4	51
375	Predictors of response to intra-articular steroid injection in psoriatic arthritis. <i>Rheumatology</i> , <b>2010</b> , 49, 1367-73	3.9	51
374	The significance of thrombocytopenia in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1983</b> , 26, 1181-6		51
373	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 345-355	9.5	51
372	Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1830-5	2.4	50
371	Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1898-906	4.1	50
370	Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 53, 404-9		49
369	Brief Report: CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 2911-2916	9.5	49

368	Contributions of observational cohort studies in systemic lupus erythematosus: the university of toronto lupus clinic experience. <i>Rheumatic Disease Clinics of North America</i> , <b>2005</b> , 31, 211-21, v	2.4	48
367	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1733-9	4.1	48
366	Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 54-65	4.1	47
365	Epigenetics of psoriatic disease: A systematic review and critical appraisal. <i>Journal of Autoimmunity</i> , <b>2017</b> , 78, 29-38	15.5	46
364	Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 875-9	4.1	46
363	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 893-902	4.7	46
362	Psoriatic arthritis. <i>Baillieres Clinical Rheumatology</i> , <b>1995</b> , 9, 319-29		46
361	Defining Low Disease Activity in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 997-1003	4.7	45
360	Early psoriatic arthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2012</b> , 38, 373-86	2.4	45
359	HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs. <i>Human Immunology</i> , <b>2003</b> , 64, 887-9	2.3	45
358	Impaired antigen-specific suppressor cell activity in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>1980</b> , 23, 1246-50		45
357	Psoriatic arthritis. <i>F1000Research</i> , <b>2019</b> , 8,	3.6	45
356	Treatment guidelines in psoriatic arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, i37-i46	3.9	44
355	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 13, 406-408		44
354	HLA markers for susceptibility and expression in scleroderma. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 1481-74.1		43
353	Tumour necrosis factor blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1007-11	2.4	42
352	Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 649-55	4.5	42
351	Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 758-65	4.7	42

350	Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?. <i>Rheumatology</i> , <b>2020</b> , 59, 1340-1346	3.9	42
349	Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 2069-70; author reply 2070	4.1	42
348	Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 866-71	4.1	41
347	Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 1990-5	4.1	41
346	The association between sonographic enthesitis and radiographic damage in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 189	5.7	38
345	Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. <i>Rheumatology</i> , <b>2014</b> , 53, 233-9	3.9	38
344	Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. <i>Human Immunology</i> , <b>2013</b> , 74, 1333-8	2.3	38
343	Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1508-12	4.1	38
342	Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 841-6	4.1	37
341	Atherosclerosis in psoriatic disease: latest evidence and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2015</b> , 7, 187-95	3.8	37
340	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1478-1487	4.7	36
339	Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand?. <i>Lupus</i> , <b>2013</b> , 22, 1243-50	2.6	36
338	Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 842-7	4.7	35
337	Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1785-91	4.1	35
336	Hyperuricemia in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , <b>2000</b> , 6, 6-9	1.1	35
335	Clinical and radiological changes during psoriatic arthritis disease progression. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1022-6	4.1	35
334	Clinically active serologically quiescent systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1960-2	4.1	35
333	Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 1785-8	4.1	35

332	Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 305-8	2.4	34
331	Current concepts in psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , <b>2002</b> , 14, 361-6	5.3	34
330	Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1591-1597	2.4	33
329	Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 408-416	9.5	33
328	Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population-Based Study. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 1084-1091	4.7	33
327	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1426-1439	4.1	33
326	Outcome measures in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 2262-9	4.1	33
325	Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 46, 740-745	5.3	32
324	Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1841-1849	4.1	32
323	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 47, 654-665	5.3	32
322	Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1885-91	4.1	31
321	Inhibition of mitogen mediated lymphocyte blastogenesis by adenosine. <i>Immunological Investigations</i> , <b>1975</b> , 4, 419-27		31
320	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. <i>RMD Open</i> , <b>2016</b> , 2, e000217	5.9	31
319	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 281-289	9.5	31
318	Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 782-91	4.1	30
317	Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1496-501	4.1	30
316	HLA antigens in North American patients with Takayasu arteritis. <i>Arthritis and Rheumatism</i> , <b>1992</b> , 35, 573-5		30
315	The Association Between Obesity and Clinical Features of Psoriatic Arthritis: A Case-control Study. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 437-443	4.1	29

314	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 697-700	4.1	29
313	Interferon- $\gamma$ induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , <b>2015</b> , 58, 100-10	15.5	29
312	Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2198-203	4.1	29
311	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 553-580	4.4	29
310	Update on biomarkers in psoriatic arthritis. <i>Current Rheumatology Reports</i> , <b>2010</b> , 12, 288-94	4.9	29
309	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 721-726	4.1	29
308	Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 118	5.7	28
307	Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? a critical appraisal. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 43, 521-5	5.3	28
306	Longitudinal analysis of fatigue in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1878-84	4.1	28
305	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 378-384	4.1	27
304	Updated guidelines for the management of axial disease in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 2286-9	4.1	27
303	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 665-81	4.1	27
302	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1932-44	9.5	27
301	The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 286-291	4.1	26
300	From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenile-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1627-1635	4.7	26
299	What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?. <i>Current Opinion in Rheumatology</i> , <b>2015</b> , 27, 91-8	5.3	26
298	Gene expression differences between psoriasis patients with and without inflammatory arthritis. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 620-623	4.3	26
297	Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 46, 174-182	5.3	26

296	Psoriatic arthritis: phenotypic variance and nosology. <i>Current Rheumatology Reports</i> , <b>2013</b> , 15, 316	4.9	26
295	Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 288-94	4.1	26
294	Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1361-5	2.4	26
293	The long-term use of azathioprine in patients with psoriatic arthritis. <i>Journal of Clinical Rheumatology</i> , <b>2001</b> , 7, 160-5	1.1	26
292	Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. <i>RMD Open</i> , <b>2019</b> , 5, e000808	5.9	26
291	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 990-995	4.1	26
290	Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 822-828	4.7	25
289	Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2013</b> , 51, 317-25	5.9	25
288	Diffuse idiopathic skeletal hyperostosis in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1367-73	4.1	25
287	Informing response criteria for psoriatic arthritis (PsA). II: Further considerations and a proposal--the PsA joint activity index. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 2559-65	4.1	25
286	Patient-reported outcome in psoriatic arthritis: a comparison of Web-based versus paper-completed questionnaires. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 2619-24	4.1	25
285	Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 288-91	4.1	25
284	Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1369-1374	4.1	24
283	Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1892-7	4.1	24
282	Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPAre trial. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1355-62	4.1	24
281	Effectiveness of psoriatic arthritis therapies. <i>Seminars in Arthritis and Rheumatism</i> , <b>2003</b> , 33, 29-37	5.3	24
280	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. <i>RMD Open</i> , <b>2019</b> , 5, e000806	5.9	24
279	Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 38	5.7	23



278	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 393-396	4.1	23
277	2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 654-64	4.1	23
276	Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1249-51	4.1	23
275	Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1440-7	4.7	23
274	Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. <i>Rheumatology</i> , <b>2010</b> , 49, 1361-6	3.9	23
273	Development of screening tools to identify psoriatic arthritis. <i>Current Rheumatology Reports</i> , <b>2010</b> , 12, 295-9	4.9	23
272	Bowel involvement in systemic lupus erythematosus: Crohn's disease or lupus vasculitis?. <i>Arthritis and Rheumatism</i> , <b>1985</b> , 28, 466-70		23
271	Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 296	5.7	23
270	Disease course patterns in systemic lupus erythematosus. <i>Lupus</i> , <b>2019</b> , 28, 114-122	2.6	23
269	Summarizing disease features over time: II. Variability measures of SLEDAI-2K. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 336-40	4.1	23
268	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 965-9	4.1	22
267	Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1573-1577		22
266	Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 567-71	4.1	22
265	Psoriatic arthritis from Wright's era until today. <i>Journal of rheumatology Supplement, The</i> , <b>2009</b> , 83, 4-8		22
264	Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis. <i>Nature Clinical Practice Rheumatology</i> , <b>2008</b> , 4, 510-1		22
263	Hospitalizations in Patients with Systemic Lupus Erythematosus in an Academic Health Science Center. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1173-1178	4.1	21
262	Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 1387-1395	4.7	21
261	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1089-1096	4.1	21

260	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 996-1005	4.1	21
259	Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 810-6	4.1	21
258	The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 362-6	4.1	21
257	Composite measures in psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 453-61	4.1	21
256	Recognizing psoriatic arthritis in the dermatology clinic. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 733-48; quiz 749-50	4.5	21
255	PSORIATIC ARTHRITIS: RECENT ADVANCES IN PATHOGENESIS AND TREATMENT. <i>Rheumatic Disease Clinics of North America</i> , <b>1992</b> , 18, 247-256	2.4	21
254	Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. <i>Rheumatology</i> , <b>2020</b> , 59, 90-98	3.9	21
253	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 72-81	4.1	21
252	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1-2	2.4	21
251	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , <b>2018</b> , 57, 677-687	3.9	20
250	The correlation between carotid artery atherosclerosis and clinical ischemic heart disease in lupus patients. <i>Lupus</i> , <b>2014</b> , 23, 1142-8	2.6	20
249	Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1517-20	4.7	20
248	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , <b>2010</b> , 12, R125	5.7	20
247	Clinical Aspects of the Spondyloarthropathies. <i>American Journal of the Medical Sciences</i> , <b>1998</b> , 316, 234-238		20
246	Recent advances in understanding and managing psoriatic arthritis. <i>F1000Research</i> , <b>2016</b> , 5, 2670	3.6	20
245	Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 391-396	4.1	20
244	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. <i>RMD Open</i> , <b>2018</b> , 4, e000669	5.9	19
243	Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 723-37	5.4	19

242	Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. <i>RMD Open</i> , <b>2017</b> , 3, e000415	5.9	19
241	Reliability of radiographic scoring methods in axial psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1417-22	4.7	19
240	HLA-DRB1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls. <i>Human Immunology</i> , <b>2001</b> , 62, 1239-44	2.3	19
239	Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 796-801	2.4	18
238	Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus. <i>Lupus</i> , <b>2009</b> , 18, 966-73	2.6	18
237	Repair of radiographic joint damage following treatment with etanercept in psoriatic arthritis is demonstrable by 3 radiographic methods. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1066-70	4.1	18
236	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 356-362	2.4	18
235	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 67-77	9.5	18
234	Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 612-617	2.4	17
233	Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	17
232	Significance of clinical evaluation of the metacarpophalangeal joint in relation to synovial/bone pathology in rheumatoid and psoriatic arthritis detected by magnetic resonance imaging. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2751-7	4.1	17
231	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status?. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 856-860	4.7	17
230	Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 2463-5	4.1	17
229	Psoriasis in systemic lupus erythematosus: a single-center experience. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 879-884	3.9	16
228	Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 294-299	3.5	16
227	A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. <i>Rheumatology</i> , <b>2018</b> , 57, 1370-1376	3.9	16
226	Functional impairment measurement in psoriatic arthritis: Importance and challenges. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 436-448	5.3	16
225	The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1227-9	4.1	16

224	Measuring participation in people with spondyloarthritis using the social role participation questionnaire. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1765-9	2.4	16
223	A variant of the IL4 I50V single-nucleotide polymorphism is associated with erosive joint disease in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 2207-8		16
222	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1333-1339	2.4	16
221	Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 674-678	4.1	15
220	Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1651-1659	9.5	15
219	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1297-1307	9.5	15
218	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). <i>Rheumatology</i> , <b>2018</b> , 57, 1777-1788	3.9	15
217	Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?. <i>Current Rheumatology Reports</i> , <b>2011</b> , 13, 346-52	4.9	15
216	The Spondyloarthritis Research Consortium of Canada registry for spondyloarthritis. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1343-8	4.1	15
215	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102340	15.5	15
214	How can we define low disease activity in systemic lupus erythematosus?. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 1035-1040	5.3	15
213	Predictive Utility of Cardiovascular Risk Prediction Algorithms in Inflammatory Rheumatic Diseases: A Systematic Review. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 928-938	4.1	15
212	Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 213-217	4.1	15
211	Classification and Outcome Measures for Psoriatic Arthritis. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 246	4.9	15
210	Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 519-534	4.1	14
209	Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2318-26	4.1	14
208	Association of variably expressed KIR3dl1 alleles with psoriatic disease. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 2261-2266	3.9	14
207	Physician scores vs patient self-report of joint and skin manifestations in psoriatic arthritis. <i>Rheumatology</i> , <b>2013</b> , 52, 705-11	3.9	14

206	Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 630-3	4.1	14
205	Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 448-52	4.1	14
204	Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis. <i>PLoS ONE</i> , <b>2019</b> , 14, e0212043	3.7	14
203	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e715-e723	14.2	14
202	Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 18	5.7	13
201	Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA). <i>RMD Open</i> , <b>2018</b> , 4, e000606	5.9	13
200	The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 638-643	5.3	13
199	Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 296	5.7	13
198	Predictors for clinical outcome in psoriatic arthritis - what have we learned from cohort studies?. <i>Expert Review of Clinical Immunology</i> , <b>2014</b> , 10, 763-70	5.1	13
197	High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 3052-3		13
196	Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review. <i>Drugs</i> , <b>2005</b> , 65, 1223-38	12.1	13
195	Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1718-23	4.1	13
194	Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 895-902	3.9	13
193	Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	13
192	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1294-1302	4.7	13
191	Mortality in psoriatic arthritis: Risk, causes of death, predictors for death. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 571-575	5.3	12
190	The Association Between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 756-762	9.5	12
189	Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. <i>Journal of Medical Economics</i> , <b>2018</b> , 21, 163-173	2.4	12

188	Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1206-11	4.1	12
187	Damage in lupus patients--what have we learned so far?. <i>Lupus</i> , <b>2013</b> , 22, 1225-31	2.6	12
186	Thrombovascular events affect quality of life in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1017-9	4.1	12
185	Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	12
184	Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 539-547	4.1	12
183	More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 90-94	4.1	12
182	From Childhood to Adulthood: Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 750-757	4.7	11
181	Further Evidence Supporting a Parent-of-Origin Effect in Psoriatic Disease. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 1586-90	4.7	11
180	Isolated hematuria and sterile pyuria may indicate systemic lupus erythematosus activity. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 437-40	4.1	11
179	Association of killer cell immunoglobulin-like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patients with lupus. <i>Lupus</i> , <b>2008</b> , 17, 793-8	2.6	11
178	Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 66-71	4.1	11
177	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 658-666	9.5	11
176	Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1700-1705	4.7	10
175	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1231-1235	4.7	10
174	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, e23	2.4	10
173	Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1440-1447	4.1	10
172	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 64-69	4.1	10
171	Magnetic Resonance Imaging in Psoriatic Arthritis: A Descriptive Study of Indications, Features and Effect on Treatment Change. <i>Journal of Clinical Rheumatology</i> , <b>2017</b> , 23, 243-245	1.1	10

170	Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 462-7	4.1	10
169	Psoriatic arthritis in Canadian clinical practice: the PsA assessment in rheumatology. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 1850-3	4.1	10
168	Psoriatic arthritis: recognition and management. <i>BioDrugs</i> , <b>1998</b> , 9, 271-8	7.9	10
167	Mixed leukocyte reaction in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>1976</b> , 19, 532-8		10
166	Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 362-368	4.1	10
165	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	10
164	Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 31	5.7	9
163	Relationship between cardiac symptoms, myocardial perfusion defects and coronary angiography findings in systemic lupus erythematosus. <i>Lupus</i> , <b>2011</b> , 20, 299-304	2.6	9
162	Gender-related differences in patients with psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , <b>2012</b> , 7, 641-649	1.5	9
161	The SLICC inception cohort for atherosclerosis. <i>Current Rheumatology Reports</i> , <b>2008</b> , 10, 281-5	4.9	9
160	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , <b>2019</b> , 95, 33-37	4.1	9
159	The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 29	5.7	9
158	Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients. <i>Pediatric Rheumatology</i> , <b>2017</b> , 15, 18	3.5	8
157	The Relationship Between Physical Examination and Ultrasonography of Large Entheses of the Achilles Tendon and Patellar Tendon Origin. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1026-1030	4.1	8
156	Identifying and Characterizing Psoriasis and Psoriatic Arthritis Patients in Ontario Administrative Data: A Population-based Study From 1991 to 2015. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1644-1651	4.1	8
155	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2018</b> , 94, 17-25	4.1	8
154	The Association of HLA-class I Genes and the Extent of Atherosclerotic Plaques in Patients with Psoriatic Disease. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1844-1851	4.1	8
153	The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, 69-76	3.9	8

152	Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 67-73	4.1	8
151	Addressing comorbidities in psoriatic disease. <i>Rheumatology International</i> , <b>2018</b> , 38, 219-227	3.6	8
150	Axial involvement in psoriatic arthritis: An update for rheumatologists. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 880-887	5.3	8
149	Clinical and genetic registries in psoriatic disease. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 1458-63	4.1	8
148	Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 486-489	2.2	8
147	Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 252-256	4.7	7
146	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1734-1740	9.5	7
145	Outcome measures in systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , <b>2013</b> , 8, S46-S53	0.5	7
144	A hot spot for systemic lupus erythematosus, but not for psoriatic arthritis, identified by spatial analysis suggests an interaction between ethnicity and place of residence. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 1579-85		7
143	Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. <i>Current Opinion in Rheumatology</i> , <b>2013</b> , 25, 164-70	5.3	7
142	Current and investigational treatment of psoriatic arthritis. <i>Expert Opinion on Investigational Drugs</i> , <b>2004</b> , 13, 139-50	5.9	7
141	Atlantoaxial subluxation in a patient with psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>1989</b> , 32, 1338-9		7
140	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1800-1808	4.7	7
139	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. <i>Lancet Rheumatology</i> , <b>2021</b> , 3, e270-e283	14.2	7
138	Measurement properties of the minimal disease activity criteria for psoriatic arthritis. <i>RMD Open</i> , <b>2019</b> , 5, e001002	5.9	7
137	Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 266-273	4.1	7
136	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 854-864	4.1	7
135	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 1137-1147	3.9	7



134	Should methotrexate remain the first-line drug for psoriasis?. <i>Lancet, The</i> , <b>2017</b> , 389, 482-483	4.0	6
133	Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1048-1051	4.1	6
132	Declining levels of serum chemokine (C-X-C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 920-927	4	6
131	Patterns of peripheral joint involvement in psoriatic arthritis-Symmetric, ray and/or row?. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 430-435	5.3	6
130	Physician Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1256-1262	4.1	6
129	AB0160 Epigenetic Studies in Maternally versus Paternally Transmitted Psoriatic Disease. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 856.1-856	2.4	6
128	FRI0509 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from opal balance, an open-label, long-term extension study <b>2017</b> ,		6
127	Early-onset obesity and risk for psoriatic arthritis. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 787-8	27.4	6
126	Psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , <b>1990</b> , 2, 577-81	5.3	6
125	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , <b>2019</b> , 95, 54-57	4.1	6
124	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , <b>2020</b> , 96, 53-57	4.1	6
123	Axial Disease in Psoriatic arthritis: The presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 464-468	5.3	6
122	Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 834-839	5.3	6
121	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2019</b> , 4, 31-58	1.1	6
120	New EULAR/ACR 2019 SLE Classification Criteria: defining ominousity in SLE. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	6
119	Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 1773-1778	3.9	5
118	Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC. <i>Frontiers in Genetics</i> , <b>2019</b> , 10, 304	4.5	5
117	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , <b>2019</b> , 58, 1259-1267	3.9	5

116	SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1401-5	4.1	5
115	Liver Abnormalities in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 847-853	4.1	5
114	Does the change in season affect disease activity in patients with psoriatic arthritis?. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1370-3	2.4	5
113	Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 2181-3	4.1	5
112	Can we identify psoriatic arthritis early?. <i>Current Rheumatology Reports</i> , <b>2008</b> , 10, 419-21	4.9	5
111	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , <b>2021</b> , 60, 4737-4747	3.9	5
110	Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1243-1249	4.7	5
109	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	5
108	Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1057-62	4.1	4
107	Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1407-9	4.1	4
106	Spondyloarthropathies: Targeted therapy for psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , <b>2009</b> , 5, 241-2	8.1	4
105	Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 522-5	4.1	4
104	Future trends in research in psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2012</b> , 89, 106-10		4
103	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	4
102	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1789-1808	4.4	4
101	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1158-1181	5.3	4
100	Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , <b>2021</b> ,	4.1	4
99	On Modelling Minimal Disease Activity. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 388-93	4.7	4

98	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1010-1012	2.4	4
97	Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1579-1588	4.7	4
96	Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 321-325	4.1	4
95	Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 852-858	4.1	4
94	Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1302-1309	4.5	4
93	Incidence of and Risk Factors for Heart Failure in Patients with Psoriatic Disease - A Cohort Study. <i>Arthritis Care and Research</i> , <b>2021</b> ,	4.7	4
92	Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 144-149	5.3	4
91	Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis. <i>Current Therapeutic Research</i> , <b>2020</b> , 93, 100601	2.4	3
90	Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 970-3	4.1	3
89	DEVELOPING AN IPAD <sup>®</sup> APPLICATION FOR DATA COLLECTION IN A RHEUMATOLOGY RESEARCH CLINIC. <i>International Journal of Technology Assessment in Health Care</i> , <b>2015</b> , 31, 99-102	1.8	3
88	The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 46, 791-797	5.3	3
87	Clinical Measures, Metrics, and Indices <b>2013</b> , 563-581		3
86	On defining musculoskeletal inflammation: a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 2214-5	4.1	3
85	The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database. <i>Journal of Rheumatology</i> , <b>2018</b> , 94, 26-29	4.1	3
84	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2020</b> , 5, 12-22	1.1	3
83	Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 459-470	3.5	3
82	Medium versus high initial prednisone dose for remission induction in lupus nephritis: A propensity score matched analysis. <i>Arthritis Care and Research</i> , <b>2021</b> ,	4.7	3
81	Depression and Anxiety Reduce the Probability of Achieving a State of Sustained Minimal Disease Activity in Patients with Psoriatic Arthritis. <i>Arthritis Care and Research</i> , <b>2021</b> ,	4.7	3

80	Evolving concepts in systemic lupus erythematosus damage assessment. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 307-308	8.1	3
79	Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1429-1435	2.4	3
78	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 547-552	5.3	3
77	Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1366-1373	4.1	3
76	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 58-66	4.1	3
75	Immunoglobulin levels in systemic lupus erythematosus: A narrative review. <i>Lupus</i> , <b>2021</b> , 30, 867-875	2.6	3
74	SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study <b>2018</b> ,		3
73	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence <b>2000</b> , 13, 406		3
72	Longitudinal cohort studies. <i>Journal of rheumatology Supplement, The</i> , <b>2005</b> , 72, 30-2		3
71	Reporting of mortality in a psoriatic arthritis clinic is primarily a function of the number of clinic contacts and not disease severity. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 2364-7	4.1	3
70	A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 49, 241-245	5.3	2
69	Toward Treating to Target in Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2015</b> , 93, 14-6		2
68	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	2
67	GRAPPA 2015 Research and Education Project Reports. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 979-85	4.1	2
66	Immunoglobulin G subclass analysis in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 2421-4	4.1	2
65	Prologue: 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1194-6	4.1	2
64	OP0042 Do We Know How and When to Stop Immunosuppressants in Lupus Patients?. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 76-76	2.4	2
63	OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial <b>2017</b> ,		2

62	Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1041-1043	4.1	2
61	AB0822 Therapeutic Response in Adalimumab-Treated Patients with Psoriatic Arthritis in Relation to Weight. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1175.1-1175	2.4	2
60	Is it time for treat to target in psoriatic arthritis?. <i>Lancet, The</i> , <b>2015</b> , 386, 2450-2	4.0	2
59	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2008. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 446-7	4.1	2
58	Biomarkers for comorbidities in psoriasis: a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 2193-5	4.1	2
57	A novel, disease-specific quality-of-life instrument for patients with SLE. <i>Nature Clinical Practice Rheumatology</i> , <b>2006</b> , 2, 132-3		2
56	SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis <b>2018</b> ,		2
55	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1789-1795	4.7	2
54	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 94	5.7	2
53	Axial Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , <b>2021</b> , 23, 35	4.9	2
52	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , <b>2021</b> , 30, 1283-1288	2.6	2
51	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 2293-2302	9.5	2
50	Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population. <i>Rheumatology International</i> , <b>2021</b> , 41, 1457-1464	3.6	2
49	Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , <b>2021</b> , 3, 550-557	3.5	2
48	Comparison Between INSPIRE and Domjan method for measuring lumbar lateral flexion in patients of psoriatic arthritis (PsA) and correlation with radiographic damage. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 1063-1066	3.9	2
47	Health Care Utilization for Musculoskeletal Issues During the Prediagnosis Period in Psoriatic Arthritis: A Population-Based Study. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 680-686	4.7	2
46	Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1223-1240	4.4	2
45	Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis <b>2001</b> , 45, 151		2

44	Prevalence and factors associated with osteoporosis and bone mineral density testing in psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	1
43	Case Report of Refractory Psoriatic Arthritis Achieving Remission Using (Black Seed Oil) Extract. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1297	4.1	1
42	Remission in psoriatic arthritis: Definition and predictors. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1494-1499	5.3	1
41	Historical Perspectives on Psoriatic Arthritis <b>2016</b> , 3-6		1
40	Management of Psoriatic Arthritis <b>2010</b> , 55-69		1
39	Assessing lupus. <i>Arthritis and Rheumatism</i> , <b>1998</b> , 41, 2276-2276		1
38	Assessment of disease activity in lupus. <i>Transfusion Science</i> , <b>1992</b> , 13, 129-134		1
37	Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 40	5.7	1
36	Current and investigational treatment of psoriatic arthritis		1
35	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211057975	3.8	1
34	Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 814-821	4.7	1
33	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. <i>Rheumatology Advances in Practice</i> , <b>2020</b> , 4, rkaa032	1.1	1
32	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1547-1551	4.1	1
31	Canadian Rheumatologists' Perspectives on Moderate Psoriatic Arthritis and Oligoarticular Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1692-1697	4.1	1
30	Response to: Can biomarkers differentiate psoriatic arthritis from osteoarthritis? by Tian. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e113	2.4	1
29	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. <i>Rheumatology</i> , <b>2021</b> , 60, 73-80	3.9	1
28	Factors Associated With Rapid Progression to Endstage Kidney Disease in Lupus Nephritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 228-231	4.1	1
27	Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2018</b> , 32, 415-426	5.3	1

26	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 1117-1124	5.3	1
25	GRAPPA 2007: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 1420-2	4.1	1
24	Correspondence on No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related Physician-reported spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> , 71, 1124-1125	2.4	1
23	Presidential Round Table: A Report from the GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 986-9	4.1	0
22	Exploring cannabis use and perspectives among psoriatic disease patients.. <i>Clinical Rheumatology</i> , <b>2022</b> , 1	3.9	0
21	Oligoarticular vs Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1824-1829	4.1	0
20	GRAPPA Historical Perspective <b>2016</b> , 7-14		
19	Dr. Tselios, reply. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1422	4.1	
18	FRI0165 The Molecular Convergence of Non-Hla Ankylosing Spondylitis Risk Genes with Autoimmune Diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 441.3-442	2.4	
17	Outcome Measures in Psoriatic Disease. <i>Current Dermatology Reports</i> , <b>2013</b> , 2, 164-171	1.5	
16	Reply. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1934	4.7	
15	SAT0404 Spot Urine Protein/Creatinine Ratio is Useful in Screening for Proteinuria but Should Not Substitute 24 hours Urine Collection Sample to Quantify Proteinuria in Lupus. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 805.2-806	2.4	
14	Spondyloarthritis <b>2012</b> , 367-379		
13	OP0095 Customized CNV microarray identified UGT2B17 as a novel susceptibility gene associated with familial ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 85.1-85	2.4	
12	Dr. Cauli, et al reply: Table 1.. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 654-654	4.1	
11	Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2008</b> , 8, 111-25	2.2	
10	Clinical Features of Psoriatic Arthritis <b>2007</b> , 11-18		
9	Spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , <b>2005</b> , 17, 393-394	5.3	

8	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis.. <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 53, 151950	5.3
7	Assessment of the Toronto Psoriatic Arthritis Screen 2 as a Screening Tool for Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2021</b> , 12034754211061085	1.6
6	Management of psoriatic arthritis <b>2015</b> , 1008-1013	
5	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 367-386	5.3
4	Disease development and outcome <b>2021</b> , 37-45	
3	Metrics in Disease Activity Measures in Systemic Lupus Erythematosus <b>2021</b> , 111-146	
2	Response to: Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominousness in SLE" by Whittall Garcia. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4
1	Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1677-1691	4.4